Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae422 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Kristine M Erlandson und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Quinolines, Hydroxymethylglutaryl-CoA Reductase Inhibitors, HIV Infections, Cardiovascular Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, ACTG Laboratory Center, NIAID NIH HHS.
Abstract (Originalsprache)
Background
Little is known about the potential benefits or harms of statins on physical function among people with human immunodeficiency virus (PWH).
Methods
REPRIEVE was a double-blind randomized controlled trial evaluating pitavastatin for primary prevention of major adverse cardiovascular events in PWH. Time to complete 10 chair rises, 4-m gait speed, grip strength, and a modified short physical performance test were assessed annually for up to 5 years in the ancillary study PREPARE and analyzed using linear mixed models.
Findings
Of 602 PWH, 52% were randomized to pitavastatin and 48% to placebo. Median age was 51 years; 18% were female at birth; 2% transgender; and 40% Black, and 18% Hispanic. Median PREPARE follow-up was 4.7 (4.3–5.0) years. Muscle symptoms (grade ≥3 or treatment-limiting) occurred in 5% of both groups. There was no evidence of decline in chair rise rate in either treatment group and no difference in the pitavastatin group compared to placebo (estimated difference −0.10 [95% confidence interval, −.30 to 0.10] rises/min/year; P = .31). Small declines over time were observed in other physical function tests in both treatment groups, with no apparent differences between groups.
Interpretation
We observed minimal declines in physical function over 5 years of follow-up among middle-aged PWH, with no differences among PWH randomized to pitavastatin compared to placebo. This finding, combined with low prevalence of myalgias, supports the long-term safety of statin therapy on physical function, when used for primary prevention of major adverse cardiovascular events among PWH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA.
- Center for Biostatistics in AIDS Research, Harvard TH Chan School of Public Health, Boston, Massachusetts, USA.
- Center on Aging and Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Department of Medicine, University of Alabama Birmingham School of Medicine, Birmingham, Alabama, USA.
- ViiV Healthcare Medical Affairs, Durham, North Carolina, USA.
- Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
ORCID-Profile: Kristine M Erlandson
Förderung
- NIDDK NIH HHS
- ACTG Laboratory Center
- NIAID NIH HHS
- Gilead Sciences
- ViiV Healthcare
- NHLBI NIH HHS
- Clinical Coordinating Center
- NCATS NIH HHS
Zitieren
APA
Erlandson, K. M., Umbleja, T., Ribaudo, H. J., Schrack, J. A., Overton, E. T., Fichtenbaum, C. J., Fitch, K. V., Roa, J. C., Diggs, M. R., Wood, K., Zanni, M. V., Bloomfield, G. S., Malvestutto, C., Aberg, J. A., Rodriguez-Barradas, M. C., Morones, R. G., Breaux, K., Douglas, P. S., Grinspoon, S. K., & Brown, T. T. (2025). Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae422
Vancouver
Erlandson KM, Umbleja T, Ribaudo HJ, Schrack JA, Overton ET, Fichtenbaum CJ, et al. Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae422
BibTeX
@article{Erlandson2025,
author = {Erlandson, Kristine M and Umbleja, Triin and Ribaudo, Heather J and Schrack, Jennifer A and Overton, Edgar T and Fichtenbaum, Carl J and Fitch, Kathleen V and Roa, Jhoanna C and Diggs, Marissa R and Wood, Kenneth and Zanni, Markella V and Bloomfield, Gerald S and Malvestutto, Carlos and Aberg, Judith A and Rodriguez-Barradas, Maria C and Morones, Rosalba Gomez and Breaux, Katherine and Douglas, Pamela S and Grinspoon, Steven K and Brown, Todd T},
title = {Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae422}
}
EUVIMED